Evaluation of Optimal Combination of Commercially Available Superparamagnetic Iron Oxide Nanoparticles and Transfection Agents for Labelling of Human Mesenchymal Stem Cells

인체 중간엽 줄기세포의 표지를 위한 상용화 된 Superparamagnetic Iron Oxide Nanoparticle과 Tansfection Agent의 적절한 병용을 위한 연구

  • Kim, Sung-Hun (Department of Radiology, College of Medicine, The Catholic University of Korea) ;
  • Oh, Soon-Nam (Department of Radiology, College of Medicine, The Catholic University of Korea) ;
  • Park, Youn-Hee (Department of Radiology, College of Medicine, The Catholic University of Korea) ;
  • Kang, Won-Kyung (Department of General Suregery, College of Medicine, The Catholic University of Korea) ;
  • Ahn, Kook-Jin (Department of Radiology, College of Medicine, The Catholic University of Korea) ;
  • Chung, Soo-Kyo (Department of Radiology, College of Medicine, The Catholic University of Korea)
  • 김성헌 (가톨릭의과대학 서울성모병원 영상의학과) ;
  • 오순남 (가톨릭의과대학 서울성모병원 영상의학과) ;
  • 박윤희 (가톨릭의과대학 서울성모병원 영상의학과) ;
  • 강원경 (가톨릭의과대학 서울성모병원 일반외과) ;
  • 안국진 (가톨릭의과대학 서울성모병원 영상의학과) ;
  • 정수교 (가톨릭의과대학 서울성모병원 영상의학과)
  • Received : 2011.11.15
  • Accepted : 2011.12.23
  • Published : 2012.04.30

Abstract

Purpose : To determine the optimal combination of commercially available superparamagnetic iron oxide (SPIO) nanoparticles with transfection agents (TA). Materials and Methods: Protamine sulfate (Pro) and poly-L-lysin (PLL) were incubated with ferumoxide and ferucarbotran in human mesenchymal stem cells at various concentrations, and cellular viability were evaluated. Cellular iron uptake was qualitatively and quantitatively evaluated. Cell visibility was assessed via MR imaging and the T2-relaxation time was calculated. Results: The cellular viabilities with ferucarbotran were more significantly decreased than those with ferumoxide (p < 0.05). Iron uptake with ferumoxide was significantly higher than that for those with with ferucarbotran. The T2-relaxation time was observed to be shorter with ferumoxide in comparison to those with ferucarbotran (p < 0.05). Ferumoxide at a concentration of 25 ${\mu}g$/ml in combination with either Pro or PLL at a concentration of 3.0 ${\mu}g$/ml did not adversely impact cell viability, maximized iron uptake, and exhibited a lower T2-relaxation time in comparison to other combinations. Conclusion: Stem cells with ferumoxide exhibited a higher cellular viability and iron uptake in comparison to ferucarbotran-treated stem cells. A 25 ${\mu}g$/ml of ferumoxide with a 3.0 ${\mu}g$/ml of TA is sufficient to label mesenchymal stem cells.

목적: 상용화 된 superparamagnetic iron oxide (SPIO) nanoparticles과 transfection agent (TA)의 최적의 병용 용량을 알아보고자 하였다. 대상과 방법: Protamine sulfate (Pro), poly-L-lysin (PLL)과 ferumoxide, ferucarbotran을 다양한 농도에서 인체 중간엽 줄기세포에서 배양하여 세포 생존능을 알아보았다. 세포 철 섭취율은 정성적으로, 정량적으로 분석하였다. 결과: Ferumoxide 처리군의 생존능과 철 섭취율은 ferucarbotrn 처리군보다 통계적으로 의미있게 높았다 (p < 0.05). T2 이완시간은 ferumoxide 처리군에서 짧았다 (p < 0.05). 25 ${\mu}g$/ml ferumoxide와 3.0 ${\mu}g$/ml Pro 또는 PLL 병용군이 최적의 조건이었다. 결론: Ferumoxide 처리군의 세포 생존능과 철 섭취율은 ferucarbotrn 처리군보다 높았다. 25 ${\mu}g$/ml ferumoxide와 3.0 ${\mu}g$/ml TA는 줄기세포 표지에 적합하다.

Keywords

References

  1. Arbab AS, Yocum GT, Kalish H, et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 2004;104:1217-1223
  2. Janic B, Rad AM, Jordan EK, et al. Optimization and validation of fepro cell labeling method. PLoS One 2009;4:e5873
  3. Mailander V, Lorenz MR, Holzapfel V, et al. Carboxylated superparamagnetic iron oxide particles label cells intracellularly without transfection agents. Mol Imaging Biol 2008;10:138-146
  4. van Buul GM, Farrell E, Kops N, et al. Ferumoxides-protamine sulfate is more effective than ferucarbotran for cell labeling: implications for clinically applicable cell tracking using MRI. Contrast Media & Molecular Imaging 2009;4:230-236
  5. Daldrup-Link HE, Rudelius M, Piontek G, et al. Migration of iron oxide-labeled human hematopoietic progenitor cells in a mouse model: in vivo monitoring with 1.5-t MR imaging equipment. Radiology 2005;234:197-205
  6. Arbab AS, Yocum GT, Wilson LB, et al. Comparison of transfection agents in forming complexes with ferumoxides, cell labeling efficiency, and cellular viability. Mol Imaging 2004;3:24-32
  7. Bulte JW, Douglas T, Witwer B, et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol 2001;19:1141-1147
  8. Josephson L, Tung CH, Moore A, Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-tat peptide conjugates. Bioconjug Chem 1999;10:186-191
  9. Kircher MF, Allport JR, Graves EE, et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic tlymphocyte trafficking to tumors. Cancer Res 2003;63:6838-6846
  10. Arbab AS, Bashaw LA, Miller BR, Jordan EK, Bulte JW, Frank JA. Intracytoplasmic tagging of cells with ferumoxides and transfection agent for cellular magnetic resonance imaging after cell transplantation: methods and techniques. Transplantation 2003;76:1123-1130
  11. Frank JA, Miller BR, Arbab AS, et al. Clinically applicable labeling of mammalian and stem cells by combining superparamagnetic iron oxides and transfection agents. Radiology 2003;228:480-487
  12. Daldrup-Link HE, Rudelius M, Oostendorp RA, et al. Targeting of hematopoietic progenitor cells with MR contrast agents. Radiology 2003;228:760-767
  13. Kraitchman DL, Heldman AW, Atalar E, et al. In vivo magnetic resonance imaging of mesenchymal stem cells in myocardial infarction. Circulation 2003;107:2290-2293
  14. Bowen CV, Zhang X, Saab G, Gareau PJ, Rutt BK. Application of the static dephasing regime theory to superparamagnetic iron-oxide loaded cells. Magn Reson Med 2002;48:52-61
  15. Frank JA, Zywicke H, Jordan EK, et al. Magnetic intracellular labeling of mammalian cells by combining (fda-approved) superparamagnetic iron oxide MR contrast agents and commonly used transfection agents. Acad Radiol 2002;9 Suppl 2:S484-487
  16. Ju S, Teng G, Zhang Y, Ma M, Chen F, Ni Y. In vitro labeling and MRI of mesenchymal stem cells from human umbilical cord blood. Magn Reson Imaging 2006;24:611-617
  17. Arbab AS, Bashaw LA, Miller BR, et al. Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology 2003;229:838-846
  18. Arbab AS, Yocum GT, Rad AM, et al. Labeling of cells with ferumoxides-protamine sulfate complexes does not inhibit function or differentiation capacity of hematopoietic or mesenchymal stem cells. NMR Biomed 2005;18:553-559
  19. Sorgi FL, Bhattacharya S, Huang L. Protamine sulfate enhances lipid-mediated gene transfer. Gene Ther 1997;4:961-968
  20. Bulte JW, Kraitchman DL, Mackay AM, Pittenger MF. Chondrogenic differentiation of mesenchymal stem cells is inhibited after magnetic labeling with ferumoxides. Blood 2004;104:3410-3412; author reply 3412-3413
  21. Bashford CL, Alder GM, Menestrina G, Micklem KJ, Murphy JJ, Pasternak CA. Membrane damage by hemolytic viruses, toxins, complement, and other cytotoxic agents. A common mechanism blocked by divalent cations. J Biol Chem 1986;261:9300-9308
  22. Strand BL, Ryan TL, In't Veld P, et al. Poly-l-lysine induces fibrosis on alginate microcapsules via the induction of cytokines. Cell Transplant 2001;10:263-275
  23. Song M, Moon WK, Kim Y, Lim D, Song IC, Yoon BW. Labeling efficacy of superparamagnetic iron oxide nanoparticles to human neural stem cells: comparison of ferumoxides, monocrystalline iron oxide, cross-linked iron oxide (clio)-nh2 and tat-clio. Korean J Radiol 2007;8:365-371
  24. Oude Engberink RD, van der Pol SM, Dopp EA, de Vries HE, Blezer EL. Comparison of spio and uspio for in vitro labeling of human monocytes: MR detection and cell function. Radiology 2007;243:467-474